Tianyin Pharmaceutical Co., Inc., a manufacturer and supplier of modernized traditional Chinese medicine based in Chengdu, China, has appointed James Jiayuan Tong, M.D. Ph.D., as its chief financial officer and Chief Business & Development Officer, effective April 1st, 2010. In addition, Tong will join the Company’s Board of Directors on April 1.
Prior to joining Tianyin, Tong was the Head of China Healthcare Investment Banking at ROTH Capital Partners, Newport Beach, CA. He initially joined ROTH as an equity research analyst, spearheading ROTH’s effort in China healthcare universe, covering a series of U.S.-listed Chinese pharmaceutical, biotech, medical devices and drug retail businesses. Prior to that, Tong was a biotechnology analyst at Rodman & Renshaw, New York, covering biotech entities focusing on molecular diagnostics and cures for Alzheimer’s disease, multiple sclerosis and cancer.
Before his Wall Street career, Tong was Principal Investigator at Marine Biological Laboratory (MBL) sponsored by Grass Foundation at Woods Hole, MA and a Senior Research Fellow at University of California, Irvine (UCI).
Tong was awarded Ph.D. in Neurobiology and Behavior from Cold Spring Harbor Laboratory / Stony Brook University Neuroscience program. He developed an innovative method to significantly extend life spans of animals based on his work on mitochondria, aging and learning disorders in Neurofibromatosis-1 (NF1) disease. He published three first-authored Nature articles and currently holds two patents. Tong received his medical degree from Peking University Health Science Center.